

RECEIVED
JAN 16 2001
TECH CENTER 1000
2001

N-W-E-L-A-D-Q-P-Q-N-L-E-E-I-L-M-H-C-Q-T,

(d) the amino acid sequence [(IV)] (SEQ ID NO:4)

T-L-K-Y-A-I-K-T-G-H-P-R-Y-F-N-Q-L-S-T-G,

(e) the amino acid sequence [(V)] (SEQ ID NO:5)

P-R-Y-F-N-Q-L-S-T-G-L-D-M-V-G-L-A-A-D-W,

(f) the amino acid sequence [(VI)] (SEQ ID NO:6)

T-Y-E-I-A-P-V-F-V-L-L-E-Y-V-T-L-K-K-M-R,

(g) the amino acid sequence [(VII)] (SEQ ID NO:7)

F-F-R-M-V-I-S-N-P-A-A-T-H-Q-D-I-D-F-L-I,

(h) a partial region [regions] of the amino acid sequence shown in (a),

(b), (c), (d), (e), (f) or/and (g) with a length of at least 6 amino acids,

wherein the peptide or peptide derivative has isoleucine as the C-terminal

amino acid, or/and

(i) an amino acid sequence which has [sequences which have] an

essentially equivalent specificity or/and affinity of binding to MHC

molecules as the amino acid sequence [sequences] shown in (a), (b), (c),

(d), (e), (f), (g) or/and (h);

wherein said peptide or peptide derivative has a length of up to 25 amino

acids.

18. (Amended) Pharmaceutical composition,

wherein

D2
Cont

it contains a peptide or peptide derivative as claimed in any one of [the] claims 1 and 2 [to 5, a peptide mimetic as claimed in claim 6 or/and a complex as claimed in one of the claims 7 to 17] as the active component if desired in combination with common pharmaceutical additives.

Please add the following new claims.

--

53. (New) A pharmaceutical composition, comprising a peptide mimetic as claimed in claim 6 as an active component if desired in combination with common pharmaceutical additives.

D3

54. (New) A pharmaceutical composition, comprising a complex as claimed in any one of claims 7 to 17 as an active component if desired in combination with common pharmaceutical additives. --

REMARKS

The amendments to the claims are made to correct improper multiple dependency or to correct grammatical inconsistencies, so the amendments do not narrow the scope of the amended claim limitations. Claim 1 is amended to introduce a limitation of isoleucine being the C-terminal amino acid in part (h) in order to more particularly pointing out and specifically claim the subject matter of what applicants consider to be the preferred embodiment of the present invention.

With the addition of claims 53 and 54, claims 1-3 and 5-54 are pending.